Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Virginia
City of Hope Medical Center
Amgen
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
University of Arizona
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
INSYS Therapeutics Inc
Northside Hospital, Inc.